Balaxi Pharmaceuticals
Balaxi Pharmaceuticals Performance
Day Range
- Low 414.00
- High 425.00
52 Week Range
- Low 399.95
- High 670.00
- Open Price414.00
- Previous Close415.95
- Volume3536
Start SIP in Balaxi Pharmaceuticals
Start SIPBalaxi Pharmaceuticals Investment Rating
-
Master Rating:
-
Balaxi Pharmaceuticals has an operating revenue of Rs. 287.94 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 17% is great, ROE of 25% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 12 which is a POOR score indicating inconsistency in earnings, a RS Rating of 6 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 17 | 25 | 30 | 23 | 28 | 26 | 21 |
Operating Expenses Qtr Cr | 16 | 21 | 25 | 20 | 25 | 22 | 17 |
Operating Profit Qtr Cr | 1 | 4 | 5 | 4 | 4 | 4 | 4 |
Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Qtr Cr | 0 | 1 | 1 | 1 | 2 | 1 | 1 |
Net Profit Qtr Cr | 1 | 3 | 4 | 4 | 4 | 5 | 4 |
Balaxi Pharmaceuticals Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 9
- Bearish Moving Average
- ___
- 7
- 20 Day
- ₹420.73
- 50 Day
- ₹429.92
- 100 Day
- ₹450.69
- 200 Day
- ₹478.12
- 20 Day
- ₹419.17
- 50 Day
- ₹427.07
- 100 Day
- ₹451.71
- 200 Day
- ₹494.91
Balaxi Pharmaceuticals Resistance and Support
Resistance | |
---|---|
First Resistance | 427.63 |
Second Resistance | 431.82 |
Third Resistance | 438.63 |
RSI | 50.95 |
MFI | 52.26 |
MACD Single Line | -2.49 |
MACD | -1.78 |
Support | |
---|---|
First Resistance | 416.63 |
Second Resistance | 409.82 |
Third Resistance | 405.63 |
Balaxi Pharmaceuticals Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 3,536 | 285,108 | 80.63 |
Week | 2,638 | 183,895 | 69.71 |
1 Month | 2,881 | 192,050 | 66.65 |
6 Month | 3,276 | 214,383 | 65.45 |
Balaxi Pharmaceuticals Result Highlights
Balaxi Pharmaceuticals Synopsis
NSE-Medical-Generic Drugs
Balaxi Pharmaceutica is involved in the business activities of Other specialized wholesale. Company’s Total Operating Revenue is Rs. 108.14 Cr. and Equity Capital is Rs. 10.18 Cr. for the Year ended 31/03/2023. Balaxi Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/09/1942 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L25191TG1942PLC121598 and registration number is 000045.Market Cap | 433 |
Sales | 95 |
Shares in Float | 0.30 |
No of funds | 3 |
Yield |
Book Value | 4.68 |
U/D Vol ratio | 0.6 |
LTDebt / Equity | |
Alpha | -0.16 |
Beta | 0.53 |
Balaxi Pharmaceuticals
Owner Name | Sep-23 | Jun-23 | May-23 | Mar-23 |
---|---|---|---|---|
Promoters | 71.22% | 71.22% | 71.22% | 71.57% |
Mutual Funds | ||||
Insurance Companies | ||||
Foreign Portfolio Investors | 18.58% | 18.58% | 18.58% | 18.66% |
Financial Institutions/ Banks | 0.03% | 0.03% | 0.03% | 0.03% |
Individual Investors | 6.62% | 6.57% | 6.48% | 5.95% |
Others | 3.55% | 3.6% | 3.69% | 3.79% |
Balaxi Pharmaceuticals Management
Name | Designation |
---|---|
Mr. Ashish Maheshwari | Managing Director |
Mrs. Minoshi Maheshwari | Non Executive Director |
Mrs. Purnima Singh Kamble | Independent Director |
Mr. M Srinivas Rao | Independent Director |
Mr. Gandhi Gamji | Independent Director |
Mr. Kunal M Bhakta | Independent Director |
Balaxi Pharmaceuticals Forecast
Price Estimates
Balaxi Pharmaceuticals Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-02 | Quarterly Results | |
2023-08-03 | Quarterly Results | |
2023-05-29 | Audited Results & Dividend | |
2023-02-01 | Quarterly Results | |
2022-11-05 | Quarterly Results |
Balaxi Pharmaceuticals FAQs
What is Share Price of Balaxi Pharmaceuticals ?
Balaxi Pharmaceuticals share price is ₹423 As on 10 December, 2023 | 22:13
What is the Market Cap of Balaxi Pharmaceuticals ?
The Market Cap of Balaxi Pharmaceuticals is ₹433.2 Cr As on 10 December, 2023 | 22:13
What is the P/E ratio of Balaxi Pharmaceuticals ?
The P/E ratio of Balaxi Pharmaceuticals is -40.9 As on 10 December, 2023 | 22:13
What is the PB ratio of Balaxi Pharmaceuticals ?
The PB ratio of Balaxi Pharmaceuticals is 2.4 As on 10 December, 2023 | 22:13